APGE · Insider Trading
Apogee Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by APGE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Michael Thomas Henderson | Chief Executive Officer | D | −920,941 | — |
| 2026-09-03 | Lisa Bollinger | Director | D | −48,780 deriv. | — |
| 2026-09-03 | William A Jones Jr | Director | D | −34,824 | — |
| 2026-09-03 | Jennifer A. Fox | Director | D | −34,824 | — |
| 2026-09-03 | Mark C. McKenna | Director | D | −20,000 | — |
| 2026-09-03 | Nimish P Shah | Director | D | −1,750,000 | −$236.44M |
| 2026-09-03 | Fairmount Funds Management LLC | Director | D | −1,772,748 | — |
| 2026-09-03 | Jane Henderson | Chief Financial Officer | D | −158,371 | — |
| 2026-09-03 | Carl Dambkowski | Chief Medical Officer | D | −168,498 | −$185.71K |
| 2026-08-11 | Tomas Kiselak | Director | M | +168,832 | +$3.98M |
| 2026-08-07 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$643.64K |
| 2026-08-07 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$643.64K |
| 2026-07-24 | Jane Henderson | Chief Financial Officer | G | −15,000 | — |
| 2026-07-16 | Carl Dambkowski | Chief Medical Officer | G | −8,000 | — |
| 2026-07-10 | Michael Thomas Henderson | Chief Executive Officer | MIXED | −95,046 | −$2.67M |
| 2026-07-02 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$635.77K |
| 2026-06-24 | Carl Dambkowski | Chief Medical Officer | Sell | −26,400 | −$3.50M |
| 2026-06-24 | Michael Thomas Henderson | Chief Executive Officer | Sell | −80,000 | −$10.60M |
| 2026-06-12 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.67M |
| 2026-06-11 | Lisa Bollinger | Director | A | +7,657 deriv. | — |
| 2026-06-11 | Tomas Kiselak | Director | A | +15,314 deriv. | — |
| 2026-06-11 | Mark C. McKenna | Director | A | +7,657 deriv. | — |
| 2026-06-11 | Nimish P Shah | Director | A | +7,657 deriv. | — |
| 2026-06-11 | Jennifer A. Fox | Director | A | +7,657 deriv. | — |
| 2026-06-11 | William A Jones Jr | Director | A | +7,657 deriv. | — |
| 2026-06-05 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$338.61K |
| 2026-05-15 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.64M |
| 2026-05-08 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$368.49K |
| 2026-05-04 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$164.08K |
| 2026-04-20 | Michael Thomas Henderson | Chief Executive Officer | M | +3,000 | +$68.58K |
| 2026-04-17 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$180.00K |
| 2026-04-10 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.65M |
| 2026-04-03 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$372.32K |
| 2026-04-03 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$170.02K |
| 2026-03-27 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$170.00K |
| 2026-03-13 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.50M |
| 2026-03-06 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$296.53K |
| 2026-03-04 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$140.43K |
| 2026-02-13 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.27M |
| 2026-02-04 | Jane Henderson | Chief Financial Officer | Sell | −2,000 | −$131.63K |
| 2026-02-04 | Carl Dambkowski | Chief Medical Officer | MIXED | −1,375 | −$267.56K |
| 2026-01-22 | Tomas Kiselak | Director | Sell | −7,000,000 | −$534.10M |
| 2026-01-16 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.62M |
| 2026-01-09 | Carl Dambkowski | Chief Medical Officer | MIXED | −4,675 | −$1.14M |
| 2026-01-06 | Carl Dambkowski | Chief Medical Officer | A | +83,690 deriv. | — |
| 2026-01-06 | Michael Thomas Henderson | Chief Executive Officer | A | +253,016 deriv. | — |
| 2026-01-06 | Jane Henderson | Chief Financial Officer | Sell | −8,000 | −$609.15K |
| 2025-12-23 | Jane Henderson | Chief Financial Officer | Sell | −1,500 | −$120.00K |
| 2025-12-12 | Michael Thomas Henderson | Chief Executive Officer | Sell | −20,000 | −$1.51M |
| 2025-12-05 | Jane Henderson | Chief Financial Officer | Sell | −1,500 | −$112.50K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Tomas Kiselak | Director | 51,166 | $6.91M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APGE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.